• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Immunoproteasome-selective inhibitors: the future of autoimmune diseases?

作者信息

Zhang Chong, Zhu Huajian, Shao Jiaan, He Ruoyu, Xi Jianjun, Zhuang Rangxiao, Zhang Jiankang

机构信息

School of Medicine, Zhejiang University City College, Hangzhou, 310015, Zhejiang Province, PR China.

Department of Pharmaceutical Preparation, Hangzhou Xixi Hospital, Hangzhou, 310023, Zhejiang Province, PR China.

出版信息

Future Med Chem. 2020 Feb;12(4):269-272. doi: 10.4155/fmc-2019-0299. Epub 2020 Jan 27.

DOI:10.4155/fmc-2019-0299
PMID:31983229
Abstract
摘要

相似文献

1
Immunoproteasome-selective inhibitors: the future of autoimmune diseases?免疫蛋白酶体选择性抑制剂：自身免疫性疾病的未来希望？
Future Med Chem. 2020 Feb;12(4):269-272. doi: 10.4155/fmc-2019-0299. Epub 2020 Jan 27.
2
Immunoproteasome-selective inhibitors: An overview of recent developments as potential drugs for hematologic malignancies and autoimmune diseases.免疫蛋白酶体选择性抑制剂：作为血液系统恶性肿瘤和自身免疫性疾病潜在药物的最新研究进展概述。
Eur J Med Chem. 2019 Nov 15;182:111646. doi: 10.1016/j.ejmech.2019.111646. Epub 2019 Aug 29.
3
The immunoproteasome: a novel drug target for autoimmune diseases.免疫蛋白酶体：自身免疫性疾病的新型药物靶点。
Clin Exp Rheumatol. 2015 Jul-Aug;33(4 Suppl 92):S74-9. Epub 2015 Oct 12.
4
The Immunoproteasome: An Emerging Target in Cancer and Autoimmune and Neurological Disorders.免疫蛋白酶体：癌症、自身免疫和神经紊乱中的新兴靶点。
J Med Chem. 2020 Mar 12;63(5):1841-1858. doi: 10.1021/acs.jmedchem.9b01226. Epub 2019 Nov 21.
5
Development of Novel Amides as Noncovalent Inhibitors of Immunoproteasomes.新型酰胺类免疫蛋白酶体非共价抑制剂的研发。
ChemMedChem. 2019 Apr 17;14(8):842-852. doi: 10.1002/cmdc.201900028. Epub 2019 Mar 26.
6
Discovery and Early Clinical Development of Selective Immunoproteasome Inhibitors.选择性免疫蛋白酶体抑制剂的发现和早期临床开发。
Cells. 2021 Dec 21;11(1):9. doi: 10.3390/cells11010009.
7
The immunoproteasome in antigen processing and other immunological functions.免疫蛋白酶体在抗原加工和其他免疫功能中的作用。
Curr Opin Immunol. 2013 Feb;25(1):74-80. doi: 10.1016/j.coi.2012.11.004. Epub 2012 Dec 6.
8
Selective immunoproteasome inhibitors with non-peptide scaffolds identified from structure-based virtual screening.通过基于结构的虚拟筛选鉴定出的具有非肽骨架的选择性免疫蛋白酶体抑制剂。
Bioorg Med Chem Lett. 2014 Aug 1;24(15):3614-7. doi: 10.1016/j.bmcl.2014.05.025. Epub 2014 May 17.
9
A patent review of immunoproteasome inhibitors.免疫蛋白酶体抑制剂的专利审查。
Expert Opin Ther Pat. 2018 Jul;28(7):517-540. doi: 10.1080/13543776.2018.1484904. Epub 2018 Jun 14.
10
Design and Evaluation of Highly Selective Human Immunoproteasome Inhibitors Reveal a Compensatory Process That Preserves Immune Cell Viability.高选择性人免疫蛋白酶体抑制剂的设计与评估揭示了一种可维持免疫细胞活力的代偿过程。
J Med Chem. 2019 Aug 8;62(15):7032-7041. doi: 10.1021/acs.jmedchem.9b00509. Epub 2019 Jul 29.

引用本文的文献

1
Shikonin Induces Glioma Necroptosis, Stemness Decline, and Impedes (Immuno)Proteasome Activity.紫草素诱导胶质瘤坏死性凋亡、干性下降，并抑制（免疫）蛋白酶体活性。
Stem Cells Int. 2024 Mar 14;2024:1348269. doi: 10.1155/2024/1348269. eCollection 2024.
2
A comprehensive review of dermatomyositis treatments - from rediscovered classics to promising horizons.皮肌炎治疗的全面综述——从重新发现的经典疗法到充满希望的新领域。
Expert Rev Clin Immunol. 2024 Feb;20(2):197-209. doi: 10.1080/1744666X.2023.2270737. Epub 2024 Jan 21.
3
Identification of a new class of proteasome inhibitors based on a naphthyl-azotricyclic-urea-phenyl scaffold.
基于萘基-氮杂三环-脲-苯基支架鉴定一类新型蛋白酶体抑制剂。
RSC Med Chem. 2023 Feb 6;14(3):573-582. doi: 10.1039/d2md00404f. eCollection 2023 Mar 22.
4
Zetomipzomib (KZR-616) attenuates lupus in mice via modulation of innate and adaptive immune responses.泽托米泊佐米（KZR-616）通过调节先天和适应性免疫应答来减轻狼疮小鼠的病情。
Front Immunol. 2023 Mar 10;14:1043680. doi: 10.3389/fimmu.2023.1043680. eCollection 2023.
5
Immunoproteasome Activity in Chronic Lymphocytic Leukemia as a Target of the Immunoproteasome-Selective Inhibitors.免疫蛋白酶体活性在慢性淋巴细胞白血病中的作用及其作为免疫蛋白酶体选择性抑制剂的靶标。
Cells. 2022 Mar 1;11(5):838. doi: 10.3390/cells11050838.
6
Deubiquitylating enzymes: potential target in autoimmune diseases.去泛素化酶：自身免疫性疾病的潜在靶点。
Inflammopharmacology. 2021 Dec;29(6):1683-1699. doi: 10.1007/s10787-021-00890-z. Epub 2021 Nov 18.
7
At the Cutting Edge against Cancer: A Perspective on Immunoproteasome and Immune Checkpoints Modulation as a Potential Therapeutic Intervention.对抗癌症的前沿领域：关于免疫蛋白酶体和免疫检查点调节作为一种潜在治疗干预措施的观点
Cancers (Basel). 2021 Sep 28;13(19):4852. doi: 10.3390/cancers13194852.
8
Immunoproteasome Function in Normal and Malignant Hematopoiesis.免疫蛋白酶体在正常和恶性造血中的功能。
Cells. 2021 Jun 22;10(7):1577. doi: 10.3390/cells10071577.
9
Synthesis and Biochemical Evaluation of Warhead-Decorated Psoralens as (Immuno)Proteasome Inhibitors.弹头修饰的补骨脂素的合成与生化评价作为（免疫）蛋白酶体抑制剂。
Molecules. 2021 Jan 12;26(2):356. doi: 10.3390/molecules26020356.
10
Immunoproteasome in IgA Nephropathy: State-of-Art and Future Perspectives.免疫蛋白酶体在 IgA 肾病中的研究进展与未来展望。
Int J Biol Sci. 2020 Jul 19;16(14):2518-2526. doi: 10.7150/ijbs.48330. eCollection 2020.